US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.
You may also be interested in...
Tests will be priced at under $5 each for low- and middle-income countries.
The US agency on 23 September granted emergency use authorization for the Assure COVID-19 IgG/IgM Rapid Test Device to be used in point-of-care settings like doctor’s offices, hospitals, urgent care centers and emergency rooms. The test requires a fingerstick to draw blood.
Germany is adjusting the national COVID-19 testing strategy, which from mid-October will include the use of antigen tests.